These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 14967061)

  • 1. A perspective on the toxicological mechanisms possibly contributing to the failure of oral glycoprotein IIb/IIIa antagonists in the clinic.
    Sy SK; Levenstadt AL
    Am J Cardiovasc Drugs; 2004; 4(1):1-10. PubMed ID: 14967061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral glycoprotein IIb/IIIa antagonists in coronary artery disease.
    Chew DP; Bhatt DL
    Curr Cardiol Rep; 2001 Jan; 3(1):63-71. PubMed ID: 11139801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral glycoprotein IIb/IIIa antagonists: new insights from the SYMPHONY trial.
    McGuire DK; Newby LK
    J Thromb Thrombolysis; 2000 Oct; 10(2):111-9. PubMed ID: 11005932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization.
    Furman MI; Krueger LA; Linden MD; Barnard MR; Frelinger AL; Michelson AD
    J Am Coll Cardiol; 2004 Jun; 43(12):2319-25. PubMed ID: 15193700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral glycoprotein IIb/IIIa antagonism in patients with coronary artery disease.
    Catella-Lawson F; Kapoor S; Moretti D; De Marco S; Vigilante GJ; Cucchiara AJ; Ramsey KE; Combe S; Rocca B; Theroux P; FitzGerald GA;
    Am J Cardiol; 2001 Aug; 88(3):236-42. PubMed ID: 11472700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].
    Galli M; Maggioni AP; Vassanelli C; Tavazzi L
    Ital Heart J Suppl; 2000 Feb; 1(2):202-11. PubMed ID: 10731377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral platelet glycoprotein IIb/IIIa receptor inhibitors--part II.
    Cannon CP
    Clin Cardiol; 2003 Sep; 26(9):401-6. PubMed ID: 14524594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycoprotein IIb/IIIa antagonists--from bench to practice.
    Casserly IP; Topol EJ
    Cell Mol Life Sci; 2002 Mar; 59(3):478-500. PubMed ID: 11964126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of platelet glycoprotein IIb/IIIa inhibitor therapy on in-hospital outcomes and long-term survival following percutaneous coronary rotational atherectomy.
    Berger JS; Slater JN; Sherman W; Green SJ; Sanborn TA; Brown DL
    J Thromb Thrombolysis; 2005 Feb; 19(1):47-54. PubMed ID: 15976967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT.
    Alexander JH; Harrington RA
    Drugs; 1998 Dec; 56(6):965-76. PubMed ID: 9878986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-platelet therapy: glycoprotein IIb-IIIa antagonists.
    Schneider DJ
    Br J Clin Pharmacol; 2011 Oct; 72(4):672-82. PubMed ID: 21906121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes.
    Braunwald E; Maseri A; Armstrong PW; Califf RM; Gibler WB; Hamm CW; Simoons ML; Van de Werf F
    Am Heart J; 1998 Apr; 135(4):S56-66. PubMed ID: 9539496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival benefit with concomitant clopidogrel and glycoprotein IIb/IIIa inhibitor therapy at ad hoc percutaneous coronary intervention.
    Gumina RJ; Yang EH; Sandhu GS; Prasad A; Bresnahan JF; Lennon RJ; Rihal CS; Holmes DR; Singh M
    Mayo Clin Proc; 2008 Sep; 83(9):995-1001. PubMed ID: 18775199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial).
    Cornel JH; Tricoci P; Lokhnygina Y; Moliterno DJ; Wallentin L; Armstrong PW; Aylward PE; Clare RM; Chen E; Leonardi S; Van de Werf F; White HD; Held C; Strony J; Mahaffey KW; Harrington RA
    Am J Cardiol; 2015 May; 115(10):1325-32. PubMed ID: 25776457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycoprotein IIb/IIIa antagonists in acute coronary syndromes: where are we now?
    Maree A; Fitzgerald DJ
    Semin Vasc Med; 2003 Nov; 3(4):385-90. PubMed ID: 15199445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral platelet glycoprotein IIb/IIIa receptor antagonists: the present challenge is safety.
    Vorchheimer DA; Fuster V
    Circulation; 1998 Feb; 97(4):312-4. PubMed ID: 9468202
    [No Abstract]   [Full Text] [Related]  

  • 17. The use of roxifiban (DMP754), a novel oral platelet glycoprotein IIb/IIIa receptor inhibitor, in patients with stable coronary artery disease.
    Murphy J; Wright RS; Gussak I; Williams B; Daly RN; Cain VA; Pieniaszek HJ; Sy SK; Ebling W; Simonson K; Wilcox RA; Kopecky SL
    Am J Cardiovasc Drugs; 2003; 3(2):101-12. PubMed ID: 14727937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
    Auer J; Berent R; Lassnig E; Weber T; Maurer E; Eber B
    Herz; 2003 Aug; 28(5):393-403. PubMed ID: 12928738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitors of the platelet receptor glycoprotein IIb-IIIa and complications during percutaneous coronary revascularization. Management strategies for the cardiac surgeon.
    Dyke C; Bhatia D
    J Cardiovasc Surg (Torino); 1999 Aug; 40(4):505-16. PubMed ID: 10532207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes.
    Bolognese L
    Curr Med Res Opin; 2007 Jun; 23(6):1217-26. PubMed ID: 17559721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.